It fits the mold. Low float, offering killed the huge run, but they always bounce back and the conference call is perfect timing for it. The offering was tiny anyways. They have 2 drugs FDA approved already. Deals always follow even if the company is a quiet one. When people are whining, Im buying.
Market Data 
Markets 
AI
